Back

Beyond LDL-cholesterol: effects of alirocumab on the human apolipoproteome

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Lipids: new pathophysiological and therapeutic insights Biomarkers ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Lukas Emanuel Schmidt

Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
Rare genetic variants in LDLR, APOB, and PCSK9 are associated with aortic stenosis
Mr S. Jurgens (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Lipidomics-based deep learning algorithms can enhance prediction of obstructive coronary artery disease
Doctor E. Karagiannidis (Thessaloniki, GR)
Abstract Slides Video
Presentation thumbnail
Peroxisome proliferator-activated receptor gamma regulates interleukin-6 induced lipoprotein(a) gene expression in human HepG2 cells
Doctor T. Harb (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
Linking antibody against apolipoprotein A-1 to metabolic dysfunction-associated steatohepatitis in mice
Doctor S. Pagano (Geneva, CH)
Abstract Slides Video
Presentation thumbnail
Electronegative ApoCIII-Rich HDL promotes cellular damage and vascular aging
Doctor W. Hsu (Yunlin, TW)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids: new pathophysiological and therapeutic insights

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Two of a kind: mass and molar immunoassay-based lipoprotein (a) concentrations are similarly prognostic for MACE risk and predictive of alirocumab benefit in ODYSSEY OUTCOMES
thumbnail
Congress Presentation
Lipoprotein (a) and lipidemic parameters in PCSK-9 inhibitor patients. Experience from a specialized centre in Greece.
thumbnail
Congress Presentation
Relation of apolipoprotein C3 to risk of major adverse cardiovascular events and death after acute coronary syndrome on a background of optimized statin treatment

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources